NASDAQ:MIST - Milestone Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 51.06 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.62
▼ -0.14 (-2.07%)

This chart shows the closing price for MIST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Milestone Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIST

Analyst Price Target is $10.00
▲ +51.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Milestone Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 51.06% upside from the last price of $6.62.

This chart shows the closing price for MIST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Milestone Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/21/2022Piper SandlerUpgradeNeutral ➝ Overweight$8.00 ➝ $10.00High
3/29/2022HC WainwrightReiterated RatingBuyMedium
3/5/2021HC WainwrightInitiated CoverageBuy$20.00High
7/29/2020OppenheimerUpgradeMarket Perform ➝ Outperform$18.00Medium
7/24/2020Jefferies Financial GroupUpgradeHold ➝ Buy$3.00 ➝ $15.00Low
7/23/2020CowenBoost Price TargetOutperform$6.00 ➝ $12.00Low
7/23/2020Piper SandlerBoost Price TargetNeutral$3.00 ➝ $8.00High
5/14/2020OppenheimerReiterated RatingHoldMedium
3/24/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $3.00High
3/24/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
3/24/2020Piper SandlerDowngradeOverweight ➝ Neutral$26.50 ➝ $3.00High
3/6/2020Piper SandlerReiterated RatingBuy$26.50Medium
3/6/2020OppenheimerReiterated RatingBuy$32.00Medium
2/21/2020CowenReiterated RatingBuy$32.00High
2/4/2020Piper SandlerReiterated RatingBuy$26.50High
11/14/2019CowenReiterated RatingBuy$32.00High
6/4/2019CIBCInitiated CoverageOutperform ➝ Outperform$32.00Low
6/4/2019OppenheimerInitiated CoverageOutperform$32.00Low
6/3/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$28.00Medium
6/3/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.50Medium
6/3/2019CowenInitiated CoverageOutperform ➝ Outperform$32.00Medium
(Data available from 8/9/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/12/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/11/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/11/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Milestone Pharmaceuticals logo
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $6.62
Low: $6.62
High: $6.62

50 Day Range

MA: $6.24
Low: $5.40
High: $7.45

52 Week Range

Now: $6.62
Low: $3.98
High: $8.24

Volume

100 shs

Average Volume

128,706 shs

Market Capitalization

$198.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Milestone Pharmaceuticals?

The following equities research analysts have issued stock ratings on Milestone Pharmaceuticals in the last twelve months: HC Wainwright, and Piper Sandler.
View the latest analyst ratings for MIST.

What is the current price target for Milestone Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Milestone Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 51.1%. Piper Sandler has the highest price target set, predicting MIST will reach $10.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $10.00 for Milestone Pharmaceuticals in the next year.
View the latest price targets for MIST.

What is the current consensus analyst rating for Milestone Pharmaceuticals?

Milestone Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIST will outperform the market and that investors should add to their positions of Milestone Pharmaceuticals.
View the latest ratings for MIST.

What other companies compete with Milestone Pharmaceuticals?

How do I contact Milestone Pharmaceuticals' investor relations team?

Milestone Pharmaceuticals' physical mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company's listed phone number is (514) 336-0444 and its investor relations email address is [email protected] The official website for Milestone Pharmaceuticals is www.milestonepharma.com. Learn More about contacing Milestone Pharmaceuticals investor relations.